Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

VEGF Receptor-2 Antagonist

Ramucirumab, LY3009806, IMC‑1121B

VEGF-Receptor-2-Antagonist

Adams RH and Alitalo K1; Hicklin DJ and Ellis LM2

Target
Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.1-3
Molecule
Ramucirumab (LY3009806, IMC-1121B) is a human IgG1 monoclonal antibody receptor antagonist that has been shown in vitro to bind to and block the activation of VEGF receptor-2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.4,5
Clinical Development
Ramucirumab is being investigated in clinical trials in patients with hepatocellular carcinoma, non-small cell lung cancer, or pediatric sarcoma.

References

  1. Adams RH, Alitalo K. Nat Rev Mol Cell Biol. 2007;8(6):464-478.
  2. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23(5):1011-1027.
  3. Olsson AK, et al. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
  4. Lu D, et al. J Biol Chem. 2003;278(44):43496-43507.
  5. Zhu Z, et al. Leukemia. 2003;17(3):604-611.
Clinical Development
Ramucirumab is being investigated in clinical trials in patients with hepatocellular carcinoma, non-small cell lung cancer, or pediatric sarcoma.

References

  1. Adams RH, Alitalo K. Nat Rev Mol Cell Biol. 2007;8(6):464-478.
  2. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23(5):1011-1027.
  3. Olsson AK, et al. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
  4. Lu D, et al. J Biol Chem. 2003;278(44):43496-43507.
  5. Zhu Z, et al. Leukemia. 2003;17(3):604-611.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

DISCOVER OTHER MOLECULES

IDH1 Inhibitor

Learn More

RET Inhibitor

Learn More

CDK4 & 6 Inhibitor

Learn More